Founded in 2011 through a collaboration between Uppsala University and Karolinska University, OssDsign AB develops and supplies orthobiologics that support bone healing. The Uppsala company now focuses solely on OssDsign Catalyst®, a nanosynthetic, silicate-substituted bone graft substitute designed for spinal fusion and other bone-healing applications. OssDsign became a pure-play orthobiologics company in 2024 after discontinuing its cranial implant business.
Code of Conduct
compliance_program
Whistleblower Procedure
compliance_program
OsteoNovusLed by co-founder and orthopedic spine surgeon Anand Agarwal, OsteoNovus develops FDA-cleared moldable bone substitutes, including its NovoGro platform, for bone repair. The company’s team brings more than 90 years of combined research experience and has performed over 10,000 orthopedic surgeries; its products are made in the USA under an ISO 13485-certified quality system.TOLEDO, OH
OrthofixFounded in 1980, Orthofix is a Lewisville, Texas-based medical technology company that develops devices and biologic solutions for spine care and limb reconstruction. Its work spans reconstructive and regenerative treatment, including bone-growth therapies and the 7D FLASH Navigation System, with products used to help patients regain mobility in more than 60 countries. Orthofix also develops biologics through its in-house tissue bank in Irvine, California, and collaborations with MTF Biologics.WAYNE, PA
Synergy Biomedical, LLCSynergy Biomedical, a privately held Wayne, Pennsylvania medical-device company, develops biomaterial bone-graft products for orthopedic and spinal surgery. Its BioSphere® technology uses spherical 45S5 bioactive-glass particles in a controlled bimodal size range, an approach the company developed to improve bone healing and distinguish its grafts from conventional irregular-particle materials. Synergy Biomedical is certified to ISO 13485 and operates a quality system aligned with FDA requirements.WAYNE, PA
SAIL FusionSAIL Fusion develops sacroiliac-joint fusion technology, applying AO Foundation principles to its proprietary BowTie SI Fusion System. The company’s posterior-inferior approach is designed around minimal tissue disruption, thorough joint preparation and rigid fixation, and its system is offered exclusively to orthopedic and neurological spine surgeons. SAIL Fusion bases its technologies on published scientific evidence and is validating BowTie through biomechanical and clinical research, including a prospective patient study initiated in 2023.SARATOGA SPRINGS, NY